- Novel Coronavirus
-
Drug Discovery Services
- Antiviral Drug Discovery
- Complement Therapy
- SARS-CoV-2 Aptamers
- Antisense Oligonucleotides
- Protease Inhibitors
- Inhibitor of Host Cell Protease
- Abelson Kinase Inhibitors
- RNA Synthesis Inhibitors
- Nucleoside Analogue
- Neuraminidase Inhibitors
- Neutralizing Antibody
- Antiviral Peptide
- Broad-spectrum Antiviral Drug
- Anti-Inflammatory Drugs
- High-Throughput Screening
- Vaccine Discovery
- Evaluation Platforms for SARS-CoV-2 Drugs
- Antiviral Drug Discovery
- IVD Immunoassays
- Products
- Resources
- About Us
Favipiravir (CAT#: Vinh-Wyb037)
| CAT | Size | Price | Quantity | |
|---|---|---|---|---|
| Vinh-Wyb037 |
|
For Research Use Only. We do not provide direct services or products for patients.
- Product Overview
- Molecular Formula: C5H4FN3O2; Molecular Weight: 157.10 g.mol-1
- CAS No.
- 259793-96-9
- Target
- SARS-CoV-2
- Molecular Formula
- C5H4FN3O2
- Molecular Weight
- 157.10 g.mol-1
- Purity
- >98%
- Introduction
- Favipiravir is a new type of RNA polymerase inhibitor used to treat new and recurrent influenza. It mainly inhibits viral proliferation by blocking viral nucleic acid replication. In the 2014 Ebola outbreak, a female nurse infected with Ebola virus in France and an infected nurse in Spain recovered after taking favipiravir. Preclinical pharmacodynamics shows that favipiravir not only exhibits antiviral activity against seasonal influenza viruses, but also against various influenza viruses of swine origin and highly pathogenic avian influenza, and does not show obvious crossover drug resistance to existing drug-resistant cell lines.
Related products
Online Inquiry
For Research Use Only. We do not provide direct services or products for patients.
For Research Use Only. We do not provide direct services or products for patients.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.